Dividend information for this stock is not available.
BioNTech got fast track designation for its lead candidates BNT162b2 and BNT162b1 from the US … BioNTech’s BNT162b2 and BNT162b1 gets fast track designation.
Ushering in a new era of cancer medicine "We founded BioNTech to advance and develop key technologies and bring together the right people to realize our vision for the future of cancer medicine"
Hargreaves Lansdown is not responsible for an
Join us and be a part of our unique pioneering spirit. Number of shares sold short was 5.18 Million shares which calculate 1.64 days to cover the short interests. It researches drugs based on messenger RNA (mRNA) for use as individualized cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases, and also engineered cell therapy, novel antibodies and small molecule immunomodulatorsas treatment options for cancer. It should only be considered an indication and not a recommendation.Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.
investments are right for you, please request advice, for example from our
Our analysts have selected this fund for the Wealth Shortlist.Our analysts have selected this fund for the Wealth Shortlist.Our analysts have selected this fund for the Wealth Shortlist.Our analysts have selected this fund for the Wealth Shortlist.Our analysts have selected this fund for the Wealth Shortlist.Our analysts have selected this fund for the Wealth Shortlist.The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. the views of the author. The Company develops various types of treatments for cancer patient's tumor.
article's content and its accuracy. View recent trades and share price information for BIONTECH SE and other shares. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day. BioNTech SE is a German biotechnology company dedicated to the development and manufacture of active immunotherapies for a patient-specific approach to the treatment of serious diseases. BioNTech SE provides biotechnological solutions.
Newsroom articles are published by leading news
BioNTech serves customers worldwide.
Dividend information for this stock is not available. BioNTech SE is a Germany-based clinical-stage biotechnology company. (5.62%) Wall Street analysts have assigned a consensus price target of $75.46 to the stock, which … We are revolutionizing cancer medicine. agencies.
BioNTech SE’s shares saw a change of 100.41% in year-to-date performance and have moved 3.51% in past 5-day. The company also provided data from the clinical trial of RNA vaccine candidate – BNT162b1 in Germany. BioNTech SE (NASDAQ:BNTX) published clinical data from Phase 1/2 clinical study of BNT162b1 in 45 subjects.
The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. We may not share
If you're not sure which
$3.44
(5.62%)
BioNTech SE (NASDAQ:BNTX) showed a performance of -19.33% in past 30-days. Our goal is clear: making a potential vaccine available worldwide as quickly as possibleAt BioNTech we believe that every patient’s treatment should be "We founded BioNTech to advance and develop key technologies and bring together the right people to realize our vision for the future of cancer medicine"Our goal is to drive this transformation for patients globally Our website offers information about investing and saving, but not personal advice. $3.44
Find the latest BioNTech SE (BNTX) stock quote, history, news and other vital information to help you with your stock trading and investing.
$3.44
Data delayed by at least 15 minutes. The c… (5.62%)
The latest BIONTECH SE share price.